Gujarat to Produce Its Own Anti-Snake Venom Within a Year, Boosting Treatment
The state of Gujarat is set to receive its first batch of region-specific anti-snake venom within approximately one year, according to an official announcement by the state government on Sunday. This development is expected to significantly enhance snakebite treatment in the state and contribute to India's national target of reducing snakebite deaths by 50% by 2030.
The Dharampur-based Snake Research Institute (SRI), which operates under the Gujarat government, has recently supplied lyophilised (freeze-dried) venom from four major venomous snake species found in the state to a licensed anti-venom manufacturer located in Telangana. The manufacturer is now tasked with producing the first region-specific anti-snake venom tailored to the snake species prevalent in Gujarat.
Region-specific anti-venom is considered more effective than generic alternatives because it targets the venom of local snake species, which can vary significantly in composition. This approach reduces the risk of adverse reactions and improves treatment outcomes for snakebite victims. Gujarat's initiative aligns with the World Health Organization's goal of halving global snakebite deaths by 2030, a target that India has also committed to meeting.
The SRI's work involves collecting venom from snakes such as the Indian cobra, common krait, Russell's viper, and saw-scaled viper, which are responsible for the majority of snakebites in Gujarat. The lyophilisation process preserves the venom's potency for research and production purposes. The partnership with the Telangana-based manufacturer marks a critical step in translating this research into a commercially available therapeutic product.
Snakebites remain a significant public health issue in India, with an estimated 58,000 deaths annually, according to recent studies. Many of these deaths are attributed to delays in accessing appropriate medical care and the use of ineffective or outdated anti-venoms. The development of region-specific anti-venoms is seen as a key strategy to improve survival rates and reduce the burden on healthcare systems.
The Gujarat government has not disclosed the cost or pricing details of the new anti-venom, but officials have indicated that efforts will be made to ensure it remains affordable and accessible to rural populations, who are most at risk of snakebites. The SRI continues to conduct research and collaborate with medical institutions to refine the production process and expand the range of snake venoms covered.
